See the DrugPatentWatch profile for keytruda

Yes, there can be variations in Keytruda (pembrolizumab) treatment durations. The U.S. Food and Drug Administration (FDA) has approved Keytruda for various types of cancers, and the treatment duration can vary depending on the type of cancer and the patient's response to the therapy [1].

In some cases, Keytruda is approved for continuous treatment until disease progression or unacceptable toxicity [1]. However, in other cases, such as in certain types of lung cancer, the treatment duration might be for a predetermined number of cycles [1].

Moreover, the National Comprehensive Cancer Network (NCCN) guidelines recommend considering various factors, such as the patient's response and potential toxicities, when determining the treatment duration [2].

It is important to note that the treatment duration should be determined by a healthcare professional who can evaluate the patient's individual circumstances and response to the therapy [1].

In addition, DrugPatentWatch.com provides information on patent expirations and potential generic entry, which could influence the cost of Keytruda treatment in the future [3].

Sources:
[1] Keytruda (pembrolizumab) prescribing information. Merck & Co., Inc. <https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf>
[2] NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer, Version 5.2021. <https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf>
[3] DrugPatentWatch.com. Keytruda (pembrolizumab) Drug Patent Information. <https://www.drugpatentwatch.com/ Drugs/Keytruda>